{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 11 of 128', 'individual symptom) (weekly average),', 'i.e., for each individual symptom, HEIS (for', 'each individual itemimpaet), DLQI, EQ-5D-', '5L, QOLHEQ, and WLQ will be', 'summarised by treatment group and domain,', 'where applicable, and analysed using the', 'MMRM approach as described above for the', 'analysis of the secondary continuous', 'endpoint.', 'Change of treatment success abbreviation', 'To avoid', 'from PaGA 0/1 to PaGA TS.', 'misunderstandings', 'between a PaGA score of', '0 (clear) or 1 (almost', 'clear) and a PaGA', 'treatment success defined', 'as achieving:', 'PaGA score of 0 (clear)', 'when classified at', 'baseline as 1 (almost', 'clear) or 2 (mild)', 'or', 'PaGA score of 0 (clear)', 'or 1 (almost clear) when', 'classified at baseline as 3', '(moderate) or 4 (severe).', 'Section 14.3.7.2', 'The following sentences have been revised:', 'Clarification of wording.', 'Efficacy over', '\"Change from baseline to each week', 'time', 'through Week 1 to 15 in HESD NRS', '(weekly average for each individual', 'symptom) (weekly average), i.e., for each', 'individual symptom\"', 'Change from baseline to each scheduled']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 12 of 128', 'assessment until Week 14 in HEIS (for each', 'individual itemimpaet).', 'Change of treatment success abbreviations', 'To avoid', 'from IGA 0/1 to IGA TS and from PaGA 0/1', 'misunderstandings', 'to PaGA TS.', 'between e.g. an IGA', 'score of 0 (clear) or 1', '(almost clear) and IGA', 'treatment success defined', 'as an IGA score of 0', '(clear) or 1 (almost clear)', 'with at least a 2-step', 'improvement.', 'Section 14.3.9.1', 'The following sentences have been', 'Adverse event of special', 'Adverse events', 'added/revised:', 'interest was added to the', '\"Adverse events of special interest will be', 'trial.', 'tabulated by treatment group.', 'Tabulations are', 'considered a more', 'AEs leading to withdrawal from trial and', 'practical and informative', 'AEs leading toor permanent discontinuation', 'way of presenting', 'of IMP will be tabulated by treatment', 'adverse events of special', 'group listed and a narrative for each will be', 'interest as well as AEs', \"given.'\", 'leading to withdrawal', 'from trial and AEs', 'leading to permanent', 'discontinuation of IMP.', 'Section 14.3.9.4', 'New section.', 'To describe statistical', 'Subject', 'handling of the subject', 'assessment of', 'assessment of local', 'local tolerability', 'tolerability.', 'Appendix 4', 'Minor revision of exclusion criterion 1:', 'To ensure exclusion of', 'Short version of', '\"Concurrent skin diseases on the hands, e.g.', 'subjects with a diagnosis', 'eligibility', 'tinea manuum\".', 'of tinea manuum.', 'criteria']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 13 of 128', 'Revision of exclusion criterion 15:', 'To further safeguard', 'Tuberculosis requiring treatment within 12', 'subjects in risk of', 'months prior to screening and/or subjects', '(re)activation of latent', 'with a positive blood test for tuberculosis', 'tuberculosis.', 'at screening (subjects with high risk of', 'latent tuberculosis must be tested).', 'Appendix 5', 'List of protocol authors deleted.', 'To reflect changes in the', 'Contact list', 'LEO Pharma A/S', 'internal procedure for', 'protocol writing.', 'Appendix 6', 'New appendix.', 'To list changes in the', 'Protocol', 'previous amendment.', 'amendment', 'history', 'Throughout', 'Minor editorial and document formatting', 'Minor, have therefore not', 'changes.', 'been summarised.']\n\n###\n\n", "completion": "END"}